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ABSTRACT
Despite the promising data on the outcome of allogeneic stem cell transplantation (SCT) in patients with
Fanconi anemia (FA), a certain percentage of these patients still experience graft failure; some of these patients
undergo second transplants, but the existing data on the outcome of the second SCT in FA patients are scarce,
with no long-term follow-up provided in many of the publications addressing this issue. This is a review of our
experience in 4 such patients who underwent second stem cell transplants using rabbit ATG only for condition-
ing. Three engrafted promptly and are alive and free of disease at 25, 23, and 21 months, respectively. We
conclude, therefore, that the use of ATG alone for conditioning before a second SCT may offer a chance of
long-term disease-free survival for FA patients who fail their first transplant.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Fanconi anemia  Second stem cell transplantation  Antithymocyte globulins  Graft failureINTRODUCTION
Presently, allogeneic stem cell transplantation
(SCT) is the only known curative modality for bone
marrow failure in patients with Fanconi anemia (FA)
[1-10]; thus, when graft failure occurs after SCT, the
prognosis is extremely grim, as the salvage options are
limited. The use of growth factors (granulocyte-colony
stimulating factor [G-CSF] or granulocyte macro-
phage colony stimulating factor [GM-CSF]) to en-
hance hematopoiesis after graft failure in general has
been associated with variable degrees of success, but
these cytokines are lineage specific and thus have no
effect on the recovery of the red blood cells or the plate-
lets [11,12]. Second transplantation may be considered
in these patients, but extreme caremust be exercised, as
FA cells are known to be exceptionally sensitive to
chemotherapy and radiation therapy; therefore, further
cytotoxic conditioning may be detrimental. We report
here our own experience in 4 patients who underwent
second SCT after conditioning only with ATG and
a review of the available literature on this subject.PATIENTS AND METHODS
Using a conditioning regimen of cyclophospha-
mide 60 mg/kg in addition to rabbit ATG (Fresenius,
Waltham, MA), 38 FA patients underwent matched
related SCT at King Faisal Specialist Hospital and
Research Center (KFSHRC) (35 from fully HLA-
matched siblings, 2 from fully HLA-matched fathers,
and 1 from a 1-antigen mismatched brother on the A
locus) during the period from April 1999 through
May 2007. All patients had received 12 or fewer blood
product transfusions and had had no other therapy
prior to SCT. Five (13%) of these patients experienced
graft failure: 1 was primary, and 4 were secondary; all 5
underwent second SCT using bonemarrows harvested
from their same respective donors. One of the 5 pa-
tients (her donor was a fully HLA-matched father)
was retransplanted 1.5 years after the 1st SCT using
cyclophosphamide 20 mg/kg, ATG, and thoracoabdo-
minal irradiation (TAI); she is currently alive with no
evidence of disease 2.5 years after the second SCT,
but is not included in this analysis. The remaining445
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related siblings) received uniform conditioning con-
sisting of only rabbit ATG (Fresenius) 10 mg/kg/day
i.v. for 3 days given on days 24, 23, 22 with
cyclosporine (CSA) as GVHD prophylaxis, and they
are the subject of this report.
Although the chimerism analysis (done by STR)
before the second SCT on all 4 patients showed differ-
ent degrees of mixed chimerism (Table 1), patients
were considered to have graft failure because all 4
were blood and platelet transfusion dependent after
the first transplant, and even though 1 patient was
maintaining an absolute neutrophil count (ANC)
around 500  106/L, the other 3 patients persistently
had ANCs below 200  106/L and were unresponsive
to G-CSF therapy. The bone marrow examinations on
all patients showed severe hypocellularity with no
evidence of engraftment 1-2 weeks before the second
SCT.
RESULTS
Three of the 4 patients engrafted promptly; the de-
tails of the second transplant are delineated in Tables 2
and 3. The conditioning was well tolerated. One
patient (UPN 1635) had evidence of Mucor infection
of the skin of her left arm before the second SCT;
she had been started on antifungal therapy and her in-
fection resolved fully after the second SCT. Another
patient (UPN 1870) had sepsis after the first SCT
and was continuously febrile; he also had pulmonary
fungal infection, and despite the second SCT and sup-
port with G-CSF, his status continued to deteriorate
and he died 41 days after the second SCT with no
evidence of engraftment. GVHD did not develop in
any patient.
Table 1. Patients’ Chimerism Results before and after the Second SCT
Patient
UPN
STR (% of donor cells
lymphoid/Myeloid)
before the 2nd SCT
Most Recent STR
(% of Donor Cells
Lymphoid/Myeloid)
after the 2nd SCT
1497 82%/67% 70%/100%
1635 83%/68% 100%/100%
1557 56%/78% 63%/99%
1870 6%/88% N/A
SCT indicates stem cell transplantation.DISCUSSION
Various definitions of graft failure exist in the liter-
ature. On a practical level, graft failure is defined as
failure to achieve or maintain a peripheral blood neu-
trophil count of 500  106/L after SCT. However,
with the advent of more sophisticated technology,
graft failure is viewed now as the inability to attain or
sustain a certain level of donor cell engraftment.
Thus, in practicality, what sometimes is considered
a graft failure may actually reflect graft insufficiency,
making the comparison of outcome in the different
studies sometimes difficult [11].
After allogeneic SCT, the rate of graft failure is
estimated to occur in around 5% of the cases [11,13],
but higher rates have been reported in certain diseases
such as severe aplastic anemia [14]. In FA patients un-
dergoing allogeneic SCT, the incidence of graft failure
varies from 1 study to another. Socie et al. [4] reported
a total of 4 graft failures (3 primary and 1 secondary) in
49 evaluable patients who underwent matched-related
SCT (8%); the conditioning consisted of CY 20 mg/
kg, and in thoracoabdominal irradiation (TAI) at 500
cGy, all 4 patients were retransplanted; 1 remains alive
and well 1.2 years at the time of the report. Farzin et al.
[5] used cyclophosphamide 20 mg/kg and TAI at 400
cGy in addition to ATG; 2 of 30 patients transplanted
for marrow aplasia (7%) developed graft failure (1 pri-
mary and 1 secondary). We used the same regimen of
cyclophosphamide/TAI/ATG at our institution on 22
FA patients, all receiving matched-related SCT, and 2
patients (9%) developed delayed graft failure and died,
1 of sepsis and 1 after progression to AML [10].
Eliminating radiation therapy from the condition-
ing of patients with acquired aplastic anemia undergo-
ing allogeneic SCT has been associated with increased
graft failure [14,15], and here we report a graft failure
rate of 13% in FA patients after conditioning with
a nonradiation containing regimen (cyclophospha-
mide 60 mg/kg and ATG only). Similarly, Bonfim
et al. [2] reported a graft failure rate of 12% in 42 FA
patients conditioned with cyclophosphamide 60 mg/
kg alone without ATG or radiation (5 graft failures:
1 primary and 4 secondary).
Fludarabine has been used increasingly in condi-
tioning FA patients in a effort to reduce the dose and
therefore the toxicity of cyclophosphamide normallyTable 2. Types of Graft Failure and Engraftment Details of the Patients at the Second SCT
Patient
UPN
Type of
Failure
CD34 Dose
1st SCT (106/kg)
CD34 dose
2nd SCT (106/kg)
Time to Graft
Failure (Months)
Time from
1st SCT to
2nd SCT (Months)
Days to ANC
.0.5  109/L
Days to Platelets
.20  109/L
1497 Secondary 7 6.0 7 10.3 11 22
1635 Primary 6 6.3 N/A 1.25 17 32
1557 Secondary 3 2.7 3 9.4 N/A 13
1870 Secondary 12 11 One week 1.5 N/A N/A
SCT indicates stem cell transplantation.
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Patient
UPN
Follow-up after
2nd (Months)
ANC at Last
Contact
Hb at
Contact
Platelets at Last
Contact Status upon Last Follow-up
1497 25 1.07  109/L 142 g/L 226  109/L Alive, with no evidence of disease
1635 23 2.23  109/L 142 g/L 208  109/L Alive, with no evidence of disease
1557 21 7.52  109/L 137 g/L 220  109/L Alive, with no evidence of disease
1870 1 N/A N/A N/A Failed, deceased
ANC indicates absolute neutrophil count; SCT, stem cell transplantation.used in the conditioning of FA patients [3,6]; it has
been shown to be associated with better engraftment
and improved survival both in the unrelated cord
blood transplant and in the unrelated donor SCT
settings [16,17].
Many factors may increase the rate of rejection
after allogeneic SCT, including repeated blood prod-
ucts transfusions before SCT and a low dose of stem
cells [11,15,18,19]. We and others have additionally
observed that the presence of myelodysplasia or clonal
abnormalities in FA patients pre-SCT may be an ad-
verse risk factor, predisposing patients to graft failure
[8]. In the series reported by Bonfim et al. [2], 4 of
the 5 patients with graft failure had marrow dysplasia
and/or abnormal cytogenetic analysis prior to SCT.
Furthermore, the 1 graft failure that occurred in the se-
ries reported by Bitan et al. [6] was in a patient with
MDS features and 18% blasts prior to SCT, and 1 of
the 2 graft failures in the report by Tan et al. [3] was
in a patient with myelodysplasia and abnormal cytoge-
netic studies before SCT. At our institution, all FA
patients with myelodysplasia and/or clonal abnormal-
ity pre-SCT receive total-body irradiation (TBI) as
part of the conditioning regimen, and we recently re-
ported our experience in 11 such patients who received
conditioning with cyclophosphamide 20 mg/kg and
TBI at 450 cGy; no graft failures were noted at
a median follow-up of 4 years [8].
The outcome of the second SCT is generally poor
and depends on multiple factors, and the results are
even more dismal in malignant disorders [11,20-22].
Guardiola et al. [21] reported on 82 consecutive
second SCT in patients with acute leukemia, aplastic
anemia, or chronic myeloid leukemia; the 100-day
transplant-related mortality (TRM) was 53%, and
the 3-year overall survival (OS) was 30%. Only 1 of
the patients transplanted for malignancies survived.
Others have also corroborated these findings
[13,15,20,22]. Guardiola et al. [21] also showed that
a longer interval between the 2 transplants ($80
days) was associated with a remarkably lower 100-
day TRM. Therefore, second allogeneic SCT may
be a viable option for many FA patients with graft fail-
ure, particularly if enough time has elapsed since the
first SCT, but further cytotoxic conditioning for these
patients may be harmful in light of the increased sensi-
tivity that FA patients demonstrate to chemotherapyand radiation therapy. The data on the toxicity pat-
terns in FA patients following a second SCT are
sketchy and scarce. Bonfimet al. [2] used a combination
of cyclophosphamide/fludarabine or cyclophospha-
mide alone on 4 FA patients undergoing a 2nd SCT:
2 had a successful outcome, 1 died, and 1 required
a 3rd SCT and was reported well 33 months after the
first SCT. Tan et al. [3] performed a second SCT on
1 patient on day 33 after the first SCT using cyclo-
phosphamide and total lymphoid irradiation, and the
patient was reported well and alive; another patient
received a second SCT 10 months after the first SCT
using cyclophosphamide and TBI, but he succumbed
to progressive disease (MDS). Bitan et al. [6] used
a combination of busulfan/fludarabine/alemtuzumab
to successfully condition 1 patient for the second SCT.
The use of anti-T cell serotherapy (ATG) alone in
the conditioning for the second SCT is not novel [19],
but this has not been widely studied in FA patients.
Farzin et al. [5] successfully used rabbit ATG alone be-
fore the infusion of marrow cells in 1 patient who failed
to engraft 27 days after matched sibling cord blood
transplantation; the same sibling was used as the
source of marrow cells.
Evidently, there are various approaches to condi-
tion FA patients for second SCT, and the outcome
appears to be better in those transplanted for second-
ary graft failure [15]. In our series, the use of ATG
alone has led to a successful outcome in 3 out of the
4 patients who underwent the procedure; 2 of them
had the second SCT because of secondary graft failure.
Despite the normalization of peripheral cell blood
counts in our 3 patients, the short tandem repeats
(STR) analysis continued to show mixed chimerism
in 2 of them (Table 1). Because full donor chimerism
is preferable in allografting FA patients to obviate later
hematologic risks of leukemia in the residual host cells,
it may be beneficial in some patients to add other
agents such as fludarabine to the ATG regimen to en-
sure complete donor chimerism.
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